Lorcaserin for the treatment of obesity? A closer look at its side effects

Open Heart

Volumn 1, Issue 1, 2014, Pages

  DiNicolantonio, James J ^a   Chatterjee, Subhankar ^b   O'Keefe, James H ^a   Meier, Pascal ^c,d  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b R G KAR MEDICAL COLLEGE   (India)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORCASERIN; PLACEBO; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR;

BARIATRIC SURGERY; BEHAVIOR THERAPY; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MALIGNANT NEOPLASM; MITRAL VALVE REGURGITATION; MORBID OBESITY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SLEEP DISORDERED BREATHING; WEIGHT REDUCTION;

EID: 85006961447     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2014-000173     Document Type: Editorial

References (21)

1. Marcason W. What are the latest figures for state-specific prevalence of obesity in the United States J Am Diet Assoc 2007;107:168.
2. Zaninotto P, Head J, Stamatakis E, et al. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. J Epidemiol Community Health 2009;63:140-6.
3. Jafar TH, Qadri Z, Islam M, et al. Rise in childhood obesity with persistently high rates of undernutrition among urban school-aged Indo-Asian children. Arch Dis Child 2008;93:373-8.
4. World Health Organization Obesity and overweight fact sheet no. 311. 2006. WHO website. http://www. who. int/mediacentre/ factsheets/fs311/en/ (accessed 7 Sep 2013).
5. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-41.
6. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009;6:e1000058.
7. Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566-75.
8. Mertens IL, van Gaal LF. Overweight, obesity, and blood pressure: The effects of modest weight reduction. Obes Res 2000;8:270-8.
9. Fontana MA, Wohlgemuth SD. The surgical treatment of metabolic disease and morbid obesity. Gastroenterol Clin North Am 2010;39:125-33.
10. Jensen C, Flum DR. The costs of nonsurgical and surgical weight loss interventions: is an ounce of prevention really worth a pound of cure Surg Obes Relat Dis 2005;1:353-7.
11. Tindle HA, Omalu B, Courcoulas A, et al. Risk of suicide after long-term follow-up from bariatric surgery. Am J Med 2010;123:1036-42.
12. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9.
13. Hopkins CR. ACS chemical neuroscience molecule spotlight on lorcaserin. ACS Chem Neurosci 2010;1:718-19.
14. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577-87.
15. Smith BM, Smith JM, Tsai JH, et al. Discovery and structure-activity relationship of (1R)-8-chloro-2, 3, 4, 5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 2008;51:305-13.
16. Bello NT and Liang N. The use of serotonergic drugs to treat obesity-is there any hope Drug Des Devel Ther 2011;5:95-109.
17. Belviq (lorcaserin hydrochloride) package insert. Zofingen, Switzerland: Arena Pharmaceuticals GmbH; June 2012. http://www. belviq. com/pdf/ Belviq-Prescribing-information. pdf (accessed 8 Sep 2013).
18. Prevalence of overweight, obesity, and extreme obesity among adults. Centers for Disease Control, 2011. http://www. cdc. gov/nchs/ data/hestat/obesity-adult-09-10/obesity-adult-09-10. htm (accessed 8 Sep 2013).
19. The FDA Lorcaserin Medical Review. http://www. Accessdata. fda. gov/drugsatfda-docs/nda/2012/022529Orig1s000MedR. pdf (accessed 8 Sep 2013).
20. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6:560-7.
21. Elangbam CS. Drug-induced valvulopathy: An update. Toxicol Pathol 2010;38:837-48.